- Home
- REVB vs PTPI Comparison
REVB vs PTPI Comparison
Compare REVB & PTPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- PTPI
- Stock Information
- Founded
- REVB 2020
- PTPI 2020
- Country
- REVB United States
- PTPI United States
- Employees
- REVB N/A
- PTPI N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- PTPI Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- PTPI Health Care
- Exchange
- REVB Nasdaq
- PTPI Nasdaq
- Market Cap
- REVB 3.1M
- PTPI 3.0M
- IPO Year
- REVB N/A
- PTPI N/A
- Fundamental
- Price
- REVB $0.80
- PTPI $0.26
- Analyst Decision
- REVB
- PTPI Strong Buy
- Analyst Count
- REVB 0
- PTPI 1
- Target Price
- REVB N/A
- PTPI $4.00
- AVG Volume (30 Days)
- REVB 1.3M
- PTPI 327.3K
- Earning Date
- REVB 11-08-2024
- PTPI 11-13-2024
- Dividend Yield
- REVB N/A
- PTPI N/A
- EPS Growth
- REVB N/A
- PTPI N/A
- EPS
- REVB N/A
- PTPI N/A
- Revenue
- REVB N/A
- PTPI $4,022,389.00
- Revenue This Year
- REVB N/A
- PTPI N/A
- Revenue Next Year
- REVB N/A
- PTPI $0.76
- P/E Ratio
- REVB N/A
- PTPI N/A
- Revenue Growth
- REVB N/A
- PTPI N/A
- 52 Week Low
- REVB $0.70
- PTPI $0.22
- 52 Week High
- REVB $25.26
- PTPI $2.27
- Technical
- Relative Strength Index (RSI)
- REVB 44.03
- PTPI 32.32
- Support Level
- REVB $0.80
- PTPI $0.30
- Resistance Level
- REVB $1.05
- PTPI $0.33
- Average True Range (ATR)
- REVB 0.07
- PTPI 0.04
- MACD
- REVB -0.00
- PTPI -0.01
- Stochastic Oscillator
- REVB 9.69
- PTPI 21.44
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About PTPI Petros Pharmaceuticals Inc.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.